Currently, there are 2.04B common shares owned by the public and among those 2.03B shares have been available to trade.
The company’s stock has a 5-day price change of -2.70% and -19.73% over the past three months. BMY shares are trading -15.31% year to date (YTD), with the 12-month market performance down to -2.22% lower. It has a 12-month low price of $39.35 and touched a high of $63.33 over the same period. BMY has an average intraday trading volume of 13.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.64%, -15.28%, and -11.07% respectively.
Institutional ownership of Bristol-Myers Squibb Co (NYSE: BMY) shares accounts for 79.85% of the company’s 2.04B shares outstanding.
It has a market capitalization of $97.48B and a beta (3y monthly) value of 0.42. The stock’s trailing 12-month PE ratio is 17.98, while the earnings-per-share (ttm) stands at $2.66. The company has a PEG of 0.25 and a Quick Ratio of 1.17 with the debt-to-equity ratio at 2.95. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.52% over the week and 4.05% over the month.
Earnings per share for the fiscal year are expected to increase by 494.82%, and -11.86% over the next financial year.
Cantor Fitzgerald coverage for the Bristol-Myers Squibb Co (BMY) stock in a research note released on April 22, 2025 offered a Neutral rating with a price target of $55. Jefferies was of a view on December 16, 2024 that the stock is Buy, while BofA Securities gave the stock Neutral rating on December 10, 2024, issuing a price target of $63. Wolfe Research on their part issued Peer Perform rating on November 15, 2024.
